New normal declared and staffed: management says the company's recent level of business has become its new baseline, and
The model's full reasoning — Q3 2016 call → NOThe user asks me to determine whether management conveys that the level of business the company is now doing has become its new normal, and whether management describes real, present-tense work to serve and continue that higher level. Let me analyze the transcript carefully. Key points from the call: 1. Chris O'Connell (CEO) says: "Overall, we delivered a solid third quarter performance with sales growing 5% and adjusted non-GAAP EPS increasing 11%." 2. On biopharmaceutical market: "our broadly defined biopharmaceutical market for Waters products and services once again led the way with 13% growth in the quarter. We saw this growth across all significant pharmaceutical workflows and in all major geographic regions. Year-to-date, our sales to the biopharmaceutical customers have grown 12%, which is particularly impressive in comparison to double-digit growth rates in the first nine months of 2015." 3. On the biopharma growth drivers: "While growth contribution can be seen across multiple and customer types, our biopharmaceutical growth continues to be strongest in smaller, specialty and biotech firms. This is further evidence of a steadily increasing diversity and balance in our core business." 4. On the pharma market sustainability, when asked about the staying power of demand: "my perspective is the pharma market we see today and that we expect to see just feels like a very steadily changing and different type of market than historical, potentially with less cyclicality, more balanced geographically, more balanced from an end customer standpoint." 5. On China: "Asia continues to be our strongest region with 13% growth... The strength of our business in Asia was highlighted by strong double-digit sales growth in China and this in comparison to a strong prior year's quarter." 6. On recurring revenues: "Waters' total recurring revenue, the combination of servicing, chemistry consumables, grew 7% in Q3." Now, the key question: Does management convey that the level of business is now the new normal? Looking at the biopharma commentary, Chris says the pharma market "feels like a very steadily changing and different type of market than historical, potentially with less cyclicality." This suggests a structural change.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ECPG | Encore Capital Group, Inc. | Q1 2024 | 2024-05-08 | B |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| AEP | American Electric Power Company, Inc. | Q3 2023 | 2023-11-02 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| EVBN | Evans Bancorp, Inc. | Q4 2016 | 2017-02-06 | B+ |
UAL · Q4 2022 → YESThe question is: Does management convey that the LEVEL OF BUSINESS THE COMPANY IS NOW DOING HAS BECOME ITS NEW NORMAL — that activity which would recently have been exceptional is now the company's cu...YES The transcript shows management framing the post-pandemic operating environment—higher margins, sustained demand recovery, capacity constraints, and investments in staffing/technology—as the new baseline for United's business. Scott Kirby explicitly states that structural changes have set the industry (and United) up for higher margins than pre-pandemic levels, with United achieving 9% adjusted pre-tax margin in H2 2022 ahead of schedule and expecting to hit it again in 2023. They describe current activity (e.g.
CRL · Q2 2022 → YESThe question is whether management conveys that the current level of business has become the new normal, meaning activity that would recently have been exceptional is now ordinary, and they're doing r...YES The transcript shows management framing the elevated activity in Safety Assessment (DSA segment) as the new baseline: backlog "well above the prior year level," "significantly above prior year levels," "unprecedented demand," "never seen this sort of commitment that far out with better pricing," and "large portion of 2023 revenue already booked.
DAL · Q2 2023 → YESThe question is: Does management convey that the LEVEL OF BUSINESS THE COMPANY IS NOW DOING HAS BECOME ITS NEW NORMAL — that activity which would recently have been exceptional is now the company's cu...YES The transcript shows management framing the current performance as the new baseline: record revenue and earnings, "highest quarterly earnings result in our history," "moves Delta beyond recovery and firmly on a great path forward," and executing ahead of the three-year plan with raised full-year guidance.